AU757510C
(en)
|
1998-08-27 |
2003-09-11 |
Medimmune Limited |
Pyrrolobenzodiazepines
|
GB9818730D0
(en)
|
1998-08-27 |
1998-10-21 |
Univ Portsmouth |
Collections of compounds
|
GB9818732D0
(en)
*
|
1998-08-27 |
1998-10-21 |
Univ Portsmouth |
Collection of compounds
|
GB9818731D0
(en)
*
|
1998-08-27 |
1998-10-21 |
Univ Portsmouth |
Compounds
|
GB0226593D0
(en)
*
|
2002-11-14 |
2002-12-24 |
Consultants Ltd |
Compounds
|
ATE421967T1
(de)
*
|
2003-03-31 |
2009-02-15 |
Council Scient Ind Res |
Nichtvernetzende pyrroloä2,1-cüä1, 4übenzodiazepine als potentielle antitumor- agentien und ihre herstellung
|
GB0321295D0
(en)
|
2003-09-11 |
2003-10-15 |
Spirogen Ltd |
Synthesis of protected pyrrolobenzodiazepines
|
GB0416511D0
(en)
*
|
2003-10-22 |
2004-08-25 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
ATE516288T1
(de)
|
2003-10-22 |
2011-07-15 |
Us Gov Health & Human Serv |
Pyrrolobenzodiazepinderivate, zusammensetzungen, die diese enthalten, und damit in zusammenhang stehende verfahren
|
JPWO2005040172A1
(ja)
*
|
2003-10-29 |
2007-03-08 |
協和醗酵工業株式会社 |
三環性プロリン誘導体
|
WO2005063760A1
(en)
*
|
2003-12-31 |
2005-07-14 |
Council Of Scientific & Industrial Research |
C-8 LINKED PYRROLO[2,1-c][1,4]BENZODIAZEPINE-ACRIDONE/ACRIDINE HYBRIDS
|
WO2005063759A1
(en)
*
|
2003-12-31 |
2005-07-14 |
Council Of Scientific And Industrial Research |
PROCESS FOR PREPARING PYRROLO[2, 1-c] [1, 4] BENZODIAZEPINE HYBRIDS
|
GB0404578D0
(en)
*
|
2004-03-01 |
2004-04-07 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
GB0404574D0
(en)
*
|
2004-03-01 |
2004-04-07 |
Spirogen Ltd |
Amino acids
|
CA2558195C
(en)
*
|
2004-03-01 |
2012-11-06 |
Spirogen Limited |
11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines
|
GB0404577D0
(en)
*
|
2004-03-01 |
2004-04-07 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
EP1723152B1
(de)
*
|
2004-03-09 |
2015-02-11 |
Spirogen Sàrl |
Pyrrolobenzodiazepine
|
US6951853B1
(en)
|
2004-03-30 |
2005-10-04 |
Council Of Scientific And Industrial Research |
Process for preparing pyrrolo[2, 1-c] [1,4] benzodiazepine hybrids
|
US7056913B2
(en)
|
2004-03-30 |
2006-06-06 |
Council Of Scientific And Industrial Research |
C8—linked pyrrolo[2,1-c][1,4]benzodiazepine-acridone/acridine hybrids
|
FR2869231B1
(fr)
*
|
2004-04-27 |
2008-03-14 |
Sod Conseils Rech Applic |
Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
|
GB0410725D0
(en)
*
|
2004-05-13 |
2004-06-16 |
Spirogen Ltd |
Pyrrolobenzodiazepine therapeutic agents
|
GB0508084D0
(en)
*
|
2005-04-21 |
2005-06-01 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
CA2604805C
(en)
*
|
2005-04-21 |
2014-05-27 |
Spirogen Limited |
Pyrrolobenzodiazepines
|
WO2007039752A1
(en)
*
|
2005-10-05 |
2007-04-12 |
Spirogen Limited |
Alkyl 4- [4- (5-oxo-2, 3, 5, 11a-tetrahyd0-5h-pyrr0l0 [2, 1-c] [1, 4] benzodiazepine-8-yloxy) -butyrylamino]-1h-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease
|
ATE527262T1
(de)
*
|
2006-01-25 |
2011-10-15 |
Sanofi Sa |
Neue tomaymycin derivate enhaltende zytotoxische mittel
|
DE102006013678A1
(de)
*
|
2006-03-24 |
2007-09-27 |
Bayerische Motoren Werke Ag |
Gleit- oder Schmiermittel und Verfahren zum Aufziehen eines Fahrzeugreifens auf eine Felge
|
EP2044122B1
(de)
|
2006-07-18 |
2018-03-28 |
Sanofi |
Antagonisten-antikörper gegen epha-2 zur krebsbehandlung
|
GB0619325D0
(en)
|
2006-09-30 |
2006-11-08 |
Univ Strathclyde |
New compounds
|
EP1914242A1
(de)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Neue Antikörper gegen CD38 zur Behandlung von Krebs
|
ES2435779T3
(es)
|
2007-07-19 |
2013-12-23 |
Sanofi |
Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico
|
US8236319B2
(en)
|
2008-04-30 |
2012-08-07 |
Immunogen, Inc. |
Cross-linkers and their uses
|
GB0813432D0
(en)
*
|
2008-07-22 |
2008-08-27 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
GB0819095D0
(en)
*
|
2008-10-17 |
2008-11-26 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
GB0819097D0
(en)
*
|
2008-10-17 |
2008-11-26 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
AU2015224492B2
(en)
*
|
2009-02-05 |
2017-04-20 |
Immunogen, Inc. |
Novel benzodiazepine derivatives
|
RU2545080C2
(ru)
|
2009-02-05 |
2015-03-27 |
Иммьюноджен, Инк. |
Новые производные бензодиазепина
|
CN104984360A
(zh)
|
2009-06-03 |
2015-10-21 |
伊缪诺金公司 |
轭合方法
|
FR2949469A1
(fr)
|
2009-08-25 |
2011-03-04 |
Sanofi Aventis |
Derives anticancereux, leur preparation et leur application en therapeutique
|
AR078470A1
(es)
|
2009-10-02 |
2011-11-09 |
Sanofi Aventis |
Anticuerpos que se unen especificamente al receptor epha2
|
US9242013B2
(en)
|
2010-04-15 |
2016-01-26 |
Seattle Genetics Inc. |
Targeted pyrrolobenzodiazapine conjugates
|
PE20130342A1
(es)
|
2010-04-15 |
2013-04-20 |
Spirogen Sarl |
Pirrolobenzodiacepinas y conjugados de las mismas
|
GB201006340D0
(en)
*
|
2010-04-15 |
2010-06-02 |
Spirogen Ltd |
Synthesis method and intermediates
|
EP2558475A1
(de)
|
2010-04-15 |
2013-02-20 |
Spirogen Sàrl |
Pyrrolobenzodiazepine zur behandlung proliferativer erkrankungen
|
FR2963007B1
(fr)
|
2010-07-26 |
2013-04-05 |
Sanofi Aventis |
Derives anticancereux, leur preparation et leur application therapeutique
|
PL2675479T3
(pl)
|
2011-02-15 |
2016-09-30 |
|
Cytotoksyczne pochodne benzodiazepiny
|
FR2972006B1
(fr)
|
2011-02-24 |
2016-03-25 |
Centre Nat Rech Scient |
Nouveaux fragments d'il-33 superactifs et leurs utilisations
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
KR101860174B1
(ko)
|
2011-09-20 |
2018-05-21 |
메디뮨 리미티드 |
표적 접합체 내의 내포를 위한 비대칭 이량체 pbd 화합물로서 피롤로벤조디아제핀
|
US9399073B2
(en)
|
2011-10-14 |
2016-07-26 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazepines
|
CN104011018B
(zh)
|
2011-10-14 |
2016-12-14 |
麦迪穆有限责任公司 |
可用于制备吡咯并苯并二氮杂卓的合成方法和中间体
|
CN110183470A
(zh)
|
2011-10-14 |
2019-08-30 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓
|
BR112014009055B1
(pt)
*
|
2011-10-14 |
2021-12-14 |
Seattle Genetics, Inc. |
Compostos pirrolobenzodiazepinas, conjugados alvos, ligante de fármaco e uso dos ditos conjugados para tratar uma doença proliferativa
|
US9526798B2
(en)
|
2011-10-14 |
2016-12-27 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazepines and targeted conjugates
|
EP2750713B1
(de)
|
2011-10-14 |
2015-09-16 |
Spirogen Sàrl |
Pyrrolobenzodiazepine und konjugate daraus
|
PE20150091A1
(es)
|
2012-02-24 |
2015-02-16 |
Stem Centrx Inc |
Anticuerpos anti-sez6 y metodos de empleo
|
CN104520324A
(zh)
|
2012-02-24 |
2015-04-15 |
施特姆森特Rx股份有限公司 |
Dll3调节剂及其使用方法
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
WO2013164593A1
(en)
|
2012-04-30 |
2013-11-07 |
Spirogen Sàrl |
Pyrrolobenzodiazepines
|
CN104540827B
(zh)
|
2012-04-30 |
2018-03-23 |
Ucl商业有限公司 |
吡咯并苯并二氮杂卓
|
AU2013256596A1
(en)
|
2012-05-01 |
2014-10-09 |
Genentech, Inc. |
Anti-PMEL17 antibodies and immunoconjugates
|
SG11201500087VA
(en)
|
2012-07-09 |
2015-02-27 |
Genentech Inc |
Immunoconjugates comprising anti-cd22 antibodies
|
JP2015523380A
(ja)
|
2012-07-09 |
2015-08-13 |
ジェネンテック, インコーポレイテッド |
抗cd79b抗体を含む免疫複合体
|
BR112015002193A2
(pt)
|
2012-08-02 |
2017-07-04 |
Genentech Inc |
anticorpos anti-etbr e imunoconjugados
|
EP2887965A1
(de)
|
2012-08-22 |
2015-07-01 |
ImmunoGen, Inc. |
Zytotoxische benzodiazepin-derivate
|
ES2660029T3
(es)
|
2012-10-12 |
2018-03-20 |
Medimmune Limited |
Conjugados de anticuerpo-pirrolobenzodiazepinas
|
CN105102068B
(zh)
|
2012-10-12 |
2018-06-01 |
Adc疗法责任有限公司 |
吡咯并苯并二氮杂卓-抗体结合物
|
KR101819404B1
(ko)
|
2012-10-12 |
2018-02-28 |
메디뮨 리미티드 |
피롤로벤조디아제핀 및 그의 컨주게이트
|
MX364329B
(es)
|
2012-10-12 |
2019-04-23 |
Medimmune Ltd |
Conjugados del anticuerpo pirrolobenzodiazepina.
|
AU2013328628B2
(en)
|
2012-10-12 |
2016-12-15 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
|
WO2014057072A1
(en)
|
2012-10-12 |
2014-04-17 |
Spirogen Sàrl |
Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
|
CA2885315C
(en)
|
2012-10-12 |
2020-06-23 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
EP2906250B1
(de)
|
2012-10-12 |
2018-05-30 |
ADC Therapeutics SA |
Pyrrolobenzodiazepin-anti-psma-antikörperkonjugate
|
PL2906253T3
(pl)
|
2012-10-12 |
2019-02-28 |
Adc Therapeutics Sa |
Koniugaty pirolobenzodiazepina-przeciwciało anty-psma
|
WO2014080251A1
(en)
|
2012-11-24 |
2014-05-30 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
CA2894959C
(en)
|
2012-12-21 |
2022-01-11 |
Spirogen Sarl |
Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
|
CN110452242A
(zh)
*
|
2012-12-21 |
2019-11-15 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓及其结合物
|
HUE043851T2
(hu)
|
2013-02-22 |
2019-09-30 |
Abbvie Stemcentrx Llc |
Anti-DLL3-antitest-PBD konjugátumok és alkalmazásuk
|
KR102066318B1
(ko)
|
2013-03-13 |
2020-01-14 |
메디뮨 리미티드 |
피롤로벤조디아제핀 및 그의 컨쥬게이트
|
BR112015023070B1
(pt)
|
2013-03-13 |
2022-06-07 |
Genentech, Inc. |
Conjugados e compostos de pirrolobenzodiazepinas, composição farmacêutica que compreende os mesmo, bem como seus usos para o tratamento de uma doença proliferativa
|
JP6444902B2
(ja)
|
2013-03-13 |
2018-12-26 |
メドイミューン・リミテッドMedImmune Limited |
ピロロベンゾジアゼピン及びその結合体
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
JP6436965B2
(ja)
|
2013-03-14 |
2018-12-12 |
ジェネンテック, インコーポレイテッド |
抗b7−h4抗体及びイムノコンジュゲート
|
BR112016002829A2
(pt)
|
2013-08-12 |
2017-09-19 |
Genentech Inc |
Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
|
JP2016538318A
(ja)
|
2013-08-28 |
2016-12-08 |
ステムセントリックス, インコーポレイテッド |
新規sez6モジュレーターおよび使用方法
|
EP3892294A1
(de)
|
2013-08-28 |
2021-10-13 |
AbbVie Stemcentrx LLC |
Konjugationsverfahren stellenspezifischer antikörper und zusammensetzungen
|
JP6282745B2
(ja)
|
2013-09-12 |
2018-02-21 |
ハロザイム インコーポレイテッド |
修飾抗上皮成長因子受容体抗体およびその使用法
|
CN105518027A
(zh)
|
2013-09-17 |
2016-04-20 |
豪夫迈·罗氏有限公司 |
使用抗lgr5抗体的方法
|
US10010624B2
(en)
|
2013-10-11 |
2018-07-03 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
WO2015052535A1
(en)
|
2013-10-11 |
2015-04-16 |
Spirogen Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
US9950078B2
(en)
|
2013-10-11 |
2018-04-24 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
GB201317982D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
GB201317981D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
RU2016122041A
(ru)
|
2013-11-06 |
2017-12-11 |
ЭББВИ СТЕМСЕНТРКС ЭлЭлСи |
Новые анти-клаудин антитела и способы их применения
|
CA2927806C
(en)
|
2013-11-27 |
2023-01-10 |
Redwood Bioscience, Inc. |
Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
|
KR20160097336A
(ko)
|
2013-12-12 |
2016-08-17 |
스템센트알엑스 인코포레이티드 |
신규 항-dpep3 항체 및 이의 사용 방법
|
PE20160712A1
(es)
|
2013-12-13 |
2016-07-26 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-cd33
|
KR20160092024A
(ko)
|
2013-12-16 |
2016-08-03 |
제넨테크, 인크. |
1-(클로로메틸)-2,3-디히드로-1H-벤조[e]인돌 이량체 항체-약물 접합체 화합물, 및 사용 및 치료 방법
|
US10308721B2
(en)
|
2014-02-21 |
2019-06-04 |
Abbvie Stemcentrx Llc |
Anti-DLL3 antibodies and drug conjugates for use in melanoma
|
ES2960619T3
(es)
|
2014-02-28 |
2024-03-05 |
Hangzhou Dac Biotech Co Ltd |
Enlazadores cargados y sus usos para la conjugación
|
GB201407816D0
(en)
*
|
2014-05-02 |
2014-06-18 |
King S College London |
Pyrrolobenzodiazepine Compounds
|
CN106414499A
(zh)
|
2014-05-22 |
2017-02-15 |
基因泰克公司 |
抗gpc3抗体和免疫偶联物
|
CA2959141A1
(en)
|
2014-08-28 |
2016-03-03 |
Bioatla, Llc |
Conditionally active chimeric antigen receptors for modified t-cells
|
EP3189057A1
(de)
|
2014-09-03 |
2017-07-12 |
ImmunoGen, Inc. |
Zytotoxische benzodiazepin-derivate
|
TWI757759B
(zh)
|
2014-09-03 |
2022-03-11 |
美商免疫原公司 |
細胞毒性苯并二氮呯衍生物
|
TW201617368A
(zh)
|
2014-09-05 |
2016-05-16 |
史坦森特瑞斯公司 |
新穎抗mfi2抗體及使用方法
|
CN106687141A
(zh)
|
2014-09-10 |
2017-05-17 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓及其缀合物
|
EP3191518B1
(de)
|
2014-09-12 |
2020-01-15 |
Genentech, Inc. |
Anti-b7-h4-antikörper und immunkonjugate
|
PT3191135T
(pt)
|
2014-09-12 |
2020-11-12 |
Genentech Inc |
Anticorpos anti-her2 e imunoconjugados
|
KR20170052600A
(ko)
|
2014-09-12 |
2017-05-12 |
제넨테크, 인크. |
시스테인 가공된 항체 및 콘주게이트
|
AR101846A1
(es)
|
2014-09-12 |
2017-01-18 |
Genentech Inc |
Anticuerpos anti-cll-1 e inmunoconjugados
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
JP6730261B2
(ja)
|
2014-09-17 |
2020-07-29 |
ジェネンテック, インコーポレイテッド |
抗her2抗体を含む免疫複合体
|
CN107148285B
(zh)
|
2014-11-25 |
2022-01-04 |
Adc治疗股份有限公司 |
吡咯并苯并二氮杂䓬-抗体缀合物
|
WO2016094837A2
(en)
|
2014-12-11 |
2016-06-16 |
Igenica Biotherapeutics, Inc. |
Anti-c10orf54 antibodies and uses thereof
|
CN107231804B
(zh)
|
2015-01-14 |
2019-11-26 |
百时美施贵宝公司 |
亚杂芳基桥连苯并二氮杂*二聚体、其缀合物及制备和使用方法
|
CA2973354A1
(en)
|
2015-01-14 |
2016-07-21 |
Bristol-Myers Squibb Company |
Benzodiazepine dimers, conjugates thereof, and methods of making and using
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
GB201510010D0
(en)
|
2015-06-09 |
2015-07-22 |
King S College London |
PDD and BPD compounds
|
EP3313854A1
(de)
|
2015-06-23 |
2018-05-02 |
Bristol-Myers Squibb Company |
Makrocyclische benzodiazepindimere, konjugate davon, herstellung und verwendung
|
CA2991973C
(en)
|
2015-07-12 |
2021-12-07 |
Suzhou M-Conj Biotech Co., Ltd. |
Bridge linkers for conjugation of a cell-binding molecule
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
KR20180038460A
(ko)
|
2015-07-21 |
2018-04-16 |
이뮤노젠 아이엔씨 |
세포독성 벤조다이아제핀 유도체의 제조 방법
|
GB201514928D0
(en)
|
2015-08-21 |
2015-10-07 |
King S College London |
PDD compounds
|
US20180339985A1
(en)
|
2015-08-21 |
2018-11-29 |
Femtogenix Limited |
Pdd compounds
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
AU2016354009B2
(en)
|
2015-11-09 |
2021-05-20 |
R.P. Scherer Technologies, Llc |
Anti-CD22 antibody-maytansine conjugates and methods of use thereof
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
KR20200087875A
(ko)
|
2016-04-15 |
2020-07-21 |
바이오아트라, 엘엘씨 |
항 Axl항체 및 이의 면역접합체와 이것들의 용도
|
JP2019522960A
(ja)
|
2016-04-21 |
2019-08-22 |
アッヴィ・ステムセントルクス・エル・エル・シー |
新規の抗bmpr1b抗体及び使用方法
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
WO2017196847A1
(en)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
|
WO2017194568A1
(en)
|
2016-05-11 |
2017-11-16 |
Sanofi |
Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
|
US11254742B2
(en)
|
2016-05-13 |
2022-02-22 |
Bioatla, Inc. |
Anti-Ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
CN109313200B
(zh)
|
2016-05-27 |
2022-10-04 |
豪夫迈·罗氏有限公司 |
用于表征位点特异性抗体-药物缀合物的生物分析性方法
|
WO2017214182A1
(en)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
CA3031559A1
(en)
|
2016-08-02 |
2018-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
|
JP2019530434A
(ja)
|
2016-08-05 |
2019-10-24 |
ジェネンテック, インコーポレイテッド |
アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
|
WO2018031662A1
(en)
|
2016-08-11 |
2018-02-15 |
Genentech, Inc. |
Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
|
US20200023072A1
(en)
|
2016-10-11 |
2020-01-23 |
Medimmune Limited |
Antibody-drug conjugates with immune-mediated therapy agents
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
CN110099682B
(zh)
|
2016-11-14 |
2023-03-31 |
杭州多禧生物科技有限公司 |
偶联连接体,含有此连接体的细胞结合分子-药物偶联物及其制备和应用
|
CA3036983A1
(en)
|
2016-11-21 |
2018-05-24 |
Cureab Gmbh |
Anti-gp73 antibodies and immunoconjugates
|
FR3059550B1
(fr)
|
2016-12-01 |
2020-01-03 |
Universite De Rouen Normandie |
Traitement des troubles causes par l'alcoolisation foetale (tcaf)
|
US11236171B2
(en)
|
2016-12-21 |
2022-02-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies specific for FLT3 and uses thereof
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
PL3544636T3
(pl)
|
2017-02-08 |
2021-12-06 |
Adc Therapeutics Sa |
Koniugaty pirolobenzodiazepina-przeciwciało
|
RS63502B1
(sr)
*
|
2017-04-18 |
2022-09-30 |
Medimmune Ltd |
Konjugati pirolobenzodiazepina
|
US20180346488A1
(en)
|
2017-04-20 |
2018-12-06 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives and conjugates thereof
|
CA3057748A1
(en)
|
2017-04-20 |
2018-10-25 |
Adc Therapeutics Sa |
Combination therapy with an anti-axl antibody-drug conjugate
|
WO2018213064A1
(en)
|
2017-05-19 |
2018-11-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibody targeting tnfer2 for cancer immunotherapy
|
US11318211B2
(en)
|
2017-06-14 |
2022-05-03 |
Adc Therapeutics Sa |
Dosage regimes for the administration of an anti-CD19 ADC
|
WO2019005208A1
(en)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
|
CA3066953A1
(en)
|
2017-06-30 |
2019-01-03 |
Lentigen Technology, Inc. |
Human monoclonal antibodies specific for cd33 and methods of their use
|
NZ761175A
(en)
|
2017-08-18 |
2024-07-26 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
KR20200061376A
(ko)
|
2017-09-29 |
2020-06-02 |
다이이찌 산쿄 가부시키가이샤 |
항체-피롤로벤조디아제핀 유도체 콘쥬게이트
|
JP2021502969A
(ja)
|
2017-11-14 |
2021-02-04 |
メドイミューン・リミテッドMedImmune Limited |
ピロロベンゾジアゼピン複合体
|
MA51184A
(fr)
|
2017-12-15 |
2020-10-21 |
Juno Therapeutics Inc |
Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés
|
TW202413360A
(zh)
|
2017-12-28 |
2024-04-01 |
美商伊繆諾金公司 |
苯二氮平衍生物
|
GB201803342D0
(en)
*
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
CN112203696A
(zh)
|
2018-05-25 |
2021-01-08 |
免疫医疗有限公司 |
吡咯并苯并二氮杂*缀合物
|
FR3081707A1
(fr)
|
2018-05-30 |
2019-12-06 |
Universite De Rouen Normandie |
Traitement des troubles neurologiques causes par l'alcoolisation foetale
|
US11939377B2
(en)
|
2018-07-12 |
2024-03-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Affinity matured CD22-specific monoclonal antibody and uses thereof
|
EP3833684A1
(de)
|
2018-08-08 |
2021-06-16 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Gegen glypican-2 gerichtete, hochaffine monoklonale antikörper und verwendungen davon
|
CA3112977A1
(en)
|
2018-10-19 |
2020-04-23 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
US20210380605A1
(en)
|
2018-10-19 |
2021-12-09 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
EP3898693A4
(de)
|
2018-12-21 |
2022-09-21 |
Avidity Biosciences, Inc. |
Anti-transferrin-rezeptor-antikörper und verwendungen davon
|
CN113490510A
(zh)
|
2019-01-08 |
2021-10-08 |
美国政府(由卫生和人类服务部的部长所代表) |
用于治疗实体瘤的靶向间皮素的跨物种单结构域抗体
|
AU2020212534A1
(en)
|
2019-01-22 |
2021-07-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-1 and methods of use
|
WO2020160156A2
(en)
|
2019-01-30 |
2020-08-06 |
Immutics, Inc. |
Anti-gal3 antibodies and uses thereof
|
EP3938372B1
(de)
|
2019-03-15 |
2023-10-25 |
MedImmune Limited |
Azetidobenzodiazepindimere und konjugate damit zur verwendung in der behandlung von krebs
|
WO2020205564A1
(en)
|
2019-03-29 |
2020-10-08 |
Immunogen, Inc. |
Cytotoxic bis-benzodiazepine derivatives and conjugates thereof with cell-binding agents for inhibiting abnormal cell growth or for treating proliferative diseases
|
JP2022552875A
(ja)
|
2019-10-22 |
2022-12-20 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
多様な固形腫瘍を処置するためのb7h3(cd276)を標的とする高親和性ナノボディ
|
CA3161573A1
(en)
|
2019-12-12 |
2021-06-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-drug conjugates specific for cd276 and uses thereof
|
CA3172111A1
(en)
|
2020-03-19 |
2021-09-23 |
Barbora MALECOVA |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
MX2022011880A
(es)
|
2020-03-27 |
2022-10-20 |
Avidity Biosciences Inc |
Composiciones y metodos para tratar distrofia muscular.
|
US20230391852A1
(en)
|
2020-10-26 |
2023-12-07 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
WO2022232612A1
(en)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Lassa virus-specific nanobodies and methods of their use
|
CN117500831A
(zh)
|
2021-06-09 |
2024-02-02 |
美国政府(由卫生和人类服务部的部长所代表) |
用于治疗实体瘤的靶向pd-l1的跨物种单结构域抗体
|
JP2024526764A
(ja)
|
2021-07-13 |
2024-07-19 |
トゥルーバインディング,インコーポレイテッド |
タンパク質凝集を防止する方法
|
AU2022345098A1
(en)
|
2021-09-16 |
2024-04-04 |
Avidity Biosciences, Inc. |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
WO2023215737A1
(en)
|
2022-05-03 |
2023-11-09 |
Genentech, Inc. |
Anti-ly6e antibodies, immunoconjugates, and uses thereof
|